Regen BioPharma (RGBP) 10-Q/A 30 Mar 17 2016 Q2 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Mar. 31, 2016	Apr. 08, 2016
Document And Entity Information
Entity Registrant Name	Regen BioPharma Inc
Entity Central Index Key	1,589,150
Document Type	10-Q/A
Document Period End Date	Mar. 31, 2016
Amendment Flag	true
Amendment Description	EXPLANATORY NOTE: THIS AMENDMENT NO.1 TO REGEN BIOPHARMA, INC’S (THE “COMPANY”) FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 2016 (“(“ORIGINAL FILING”) IS BEING FILED SOLELY TO AMEND THE FOLLOWING PORTIONS OF THE ORIGINAL FILING. PART 1, ITEM 1 FINANCIAL STATEMENTS PART 1, ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. THE COMPANY HAS NOT MODIFIED OR UPDATED DISCLOSURES PRESENTED IN THE ORIGINAL FILING, EXCEPT AS INDICATED ABOVE. ACCORDINGLY, THIS AMENDMENT DOES NOT REFLECT EVENTS OCCURRING AFTER THE DATE OF THE ORIGINAL FILING AND DOES NOT MODIFY OR UPDATE THOSE DISCLOSURES AFFECTED BY SUBSEQUENT EVENTS, EXCEPT AS SPECIFICALLY REFERENCED HEREIN. INFORMATION NOT AFFECTED BY THE ABOVE AMENDMENTS IS UNCHANGED AND REFLECTS THE DISCLOSURES MADE AT THE TIME OF THE ORIGINAL FILING.
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		128,253,938
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,016

Balance Sheet (Unaudited)

Balance Sheet (Unaudited) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Restatement
CURRENT ASSETS
Cash	$ 106,024	$ 38,620
Note Receivable	12,051	12,051
Prepaid Expenses	1,000	10,000
Accrued Interest Receivable	1,978	1,381
Due from Former Employees	15,000
Total Current Assets	136,053	62,052
OTHER ASSETS
Available for Sale Securities	56,800	158,400
Total Other Assets	56,800	158,400
TOTAL ASSETS	192,853	220,452
Convertivle Notes Payable	58,295
Current Liabilities:
Bank Overdraft	0	0
Accounts payable	21,283	25,854
Notes Payable	228,050	222,751
Accrued payroll taxes	1,946	1,940
Accrued Interest	31,184	21,093
Accrued Rent	15,000	10,000
Accrued Payroll	92,996	36,001
Due to Shareholder	0
Total Current Liabilities	390,459	317,639
Total Long Term Liabilities	58,295
Total Liabilities	448,754	317,639
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 114,753,938 issued and outstanding as of September 30, 2015 and 128,253,138 shares issued and outstanding March 31, 2016	12,824	11,474
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of March 31, 2016 and September 30, 2015 respectively
Additional Paid in capital	4,038,835	2,679,473
Contributed Capital	728,658	728,658
Retained Earnings (Deficit) accumulated during the development stage	(4,909,508)	(3,489,293)
Accumulated other comprehensive income	(135,200)	(33,600)
Total Stockholders' Equity (Deficit)	(255,900)	(97,187)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	192,853	220,452
Restatement | Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of March 31, 2016 and September 30, 2015 respectively	8,488	6,098
Restatement | Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of March 31, 2016 and September 30, 2015 respectively	$ 3
Adjustments | Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of March 31, 2016 and September 30, 2015 respectively		$ 3

Balance Sheet (Unaudited) (Pare

Balance Sheet (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2016	Sep. 30, 2015
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	128,253,138	114,753,938
Common stock, shares outstanding	128,253,138	114,753,938
Preferred stock, par value	$ 0.0001	$ .0001
Preferred stock, shares authorized	800,000,000	100,000,000
Series A Preferred Stock
Preferred stock, par value	$ .0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	90,000,000
Preferred stock, shares issued	84,881,697	60,981,697
Preferred stock, shares outstanding	84,881,697	60,981,697
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares issued	30,000	30,000
Preferred stock, shares outstanding	30,000	30,000

Statement of Operations (Unaudi

Statement of Operations (Unaudited) - Restatement - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
REVENUES	$ 0	$ 0	$ 0	$ 0
COST AND EXPENSES
Research and Development	172,596	22,969	277,919	25,206
General and Administrative	435,236	303,536	923,831	442,989
Consulting and Professional Fees	97,547	279,913	178,080	339,761
Rent	15,000	15,000	30,000	26,871
Total Costs and Expenses	720,379	621,419	1,409,830	834,828
OPERATING LOSS	(720,379)	(621,419)	(1,409,830)	(834,828)
OTHER INCOME & (EXPENSES)
Interest Income	297	291	597	551
Refunds of amounts previously paid
Interest Expense	(5,089)	(9,188)	(10,090)	(15,230)
Interest Expense attributable to Amortization Discount	(894)		(894)
Preferred shares issued pursuant to contractual obligations		(3,154)		(3,154)
TOTAL OTHER INCOME (EXPENSE)	(5,686)	(12,051)	(10,387)	(17,833)
Net Income (Loss)	$ (726,064)	$ (633,470)	$ (1,420,217)	$ (852,661)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.0058)	$ (0.0088)	$ (0.0091)	$ (0.0092)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	124,875,119	71,986,230	156,418,573	93,139,424

Statement of Comprehensive Inco

Statement of Comprehensive Income (Unaudited) - Restatement - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Net Income (Loss)	$ (726,064)	$ (633,470)	$ (1,420,217)	$ (852,661)
Add:
Unrealized Gains on Securities	0	0	0	0
Less:
Unrealized Losses on Securities	(63,200)	0	(101,600)	0
Total Other Comprehensive Income (Loss)	(63,200)	0	(101,600)	0
Comprehensive Income	$ (789,264)	$ (633,470)	$ (1,521,817)	$ 852,661

Statement of Cash Flows (Unaudi

Statement of Cash Flows (Unaudited) - Restatement - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (1,420,217)	$ (852,661)
Adjustments to reconcile net Income to net cash
Preferred Stock issued for Expenses		100
Preferres Stock issued for Interest		891
Preferred Stock issued pursuant to contractual obligations		3,154
Common Stock issued to Consultants		226,177
Preferred Stock issued to Consultants	40	420
Increase (Decrease) in Interest expense attributable to amortization of Discount	894
Increase (Decrease) in Accounts Payable	(4,571)	12,902
(Increase) Decrease in Notes Receivable		(1,629)
(Increase) Decrease in Interest Receivable	(597)	(551)
Increase (Decrease) in Bank Overdraft		(6,137)
Increase (Decrease) in Accrued Expenses	72,093	19,437
(Increase) Decrease in Prepaid Expenses	9,000
(Increase) Decrease in Due from Former Employee	(15,000)
Increase in Additional Paid in Capital	495,462	132,603
Net Cash Provided by (Used in) Operating Activities	(862,896)	(465,294)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash	475,000
Preferred Stock issued for Cash	350,001
Increase in Contributed Capital		85,000
Increase (Decrease) in Notes Payable	5,299	19,582
Increase in Convertible Notes Payable	100,000	882,685
Increase in Due to Shareholder	0
Net Cash Provided by (Used in) Financing Activities	930,300	987,267
Net Increase (Decrease) in Cash	67,404	521,974
Cash at Beginning of Period	38,620	0
Cash at End of Period	106,024	521,974
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt		882,868
Preferred Shares Issued for Debt		$ 6,000

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a controlled subsidiary of Bio-Matrix Scientific Group, Inc, (“BMSN”) a Delaware corporation. The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. D. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized. E. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. F. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31, 2016 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. G. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. H. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended March 31, 2016 and $0 for the three months ended March 31, 2015.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows. In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Going Concern

Going Concern	6 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 15,421,576 during the period from April 24, 2012 (inception) through March 31, 2016. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. During the quarter ended March 31, 2015 the Company raised $265,000 through the issuance of equity securities for cash and $100,000 through the issuance of convertible debentures. During the six months ended March 31, 2016 the Company raised $825,001 through the issuance of equity securities for cash and $100,000 through the issuance of convertible debentures.

Notes Payable

Notes Payable	6 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Notes Payable	NOTE 4. NOTES PAYABLE March 31, 2016 David Koos ( Note 8) 50 Bio Technology Partners Business Trust 36,000 Bostonia Partners 189,000 Blackbriar Partners (Note 8) 3,000 Notes payable $ 228,050 $50 lent to the Company by David Koos. is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum. $36,000 lent to the Company by Bio Technology Partners Business Trust. is due and payable at the demand of the holder and bears simple interest at a rate of 10% per annum. $60,000 lent to the Company by Bostonia Partners is due and payable September 16, 2016 and bears simple interest at a rate of 10% per annum $59,000 lent to the Company by Bostonia Partners is due and payable September 22, 2016 and bears simple interest at a rate of 10% per annum. $20,000 lent to the Company by Bostonia Partners is due and payable February 19, 2017 and bears simple interest at a rate of 10% per annum. $30,000 lent to the Company by Bostonia Partners is due and payable February 24, 2017 and bears simple interest at a rate of 10% per annum. $20,000 lent to the Company by Bostonia Partners is due and payable March 8, 2017 and bears simple interest at a rate of 10% per annum. $3,000 lent to the Company by Blackbriar Partners is due and payable February 19, 2017 and bears simple interest at a rate of 10% per annum.

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 5. CONVERTIBLE NOTES PAYABLE On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). 10 (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of March 31, 2016 the unamortized discount on the convertible notes outstanding is $ 41,705. As of March 31, 2016 $100,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2016 is $25,000.

Notes Receivable

Notes Receivable	6 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Notes Receivable	NOTE 6. NOTES RECEIVABLE March 31, 2016 Entest Biomedical, Inc. (Note 8) $ 12,051 Notes Receivable $ 12,051 $12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

Income Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 7. INCOME TAXES As of March 31, 2016 Deferred tax assets: Net operating tax carry forwards $ 5,243,336 Other -0- Gross deferred tax assets 5,243,336 Valuation allowance (5,243,336 Net deferred tax assets $ -0- As of March 31, 2016 the Company has a Deferred Tax Asset of $5,243,336 completely attributable to net operating loss carry forwards of approximately $15,421,576 (which expire 20 years from the date the loss was incurred). Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. As a result, the Company has recorded a valuation allowance reducing all deferred tax assets to 0. Income tax is calculated at the 34% Federal Corporate Rate.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 8. RELATED PARTY TRANSACTIONS As of June 30, 2015 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090. The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month. As of March 31, 2016 Entest Biomedical Inc. is indebted to the Company in the amount of $12,051. $12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. As of September 30, 2015 the Company was indebted to BMSN in the amount of $19,701. $19,701 lent to the Company by Bio Matrix Scientific Group, Inc. was due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. During the quarter ended December 31, 2015 the Company repaid $19,701 of principal indebtedness due and payable to BMSN. David R. Koos, the Chairman and Chief Executive Officer of the Company, also serves as Chairman and Chief Executive Officer of BMSN. Primarily resulting from BMSN’s ownership of 30,000 shares of the Company’s Series AA Preferred Stock, BMSN possesses the majority of the shareholder voting power . As of March 31, 2016 the Company is indebted to David R. Koos in the amount of $50. $50 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. As of March 31, 2016 the Company is indebted to Blackbriar Partners in the amount of $3,000. $3,000 lent to the Company by Blackbriar Partners is due and payable February 29, 2017 and bears simple interest at a rate of 10% per annum. David R. Koos, the Chairman and Chief Executive Officer of the Company, also serves as the Chairman and CEO of Blackbriar Partners. On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is a wholly owned subsidiary of Entest Biomedical, Inc. Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on the first anniversary of the effective date of the Agreement and each subsequent anniversary. The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander or in common stock of Entest BioMedical Inc. valued as of the lowest closing price on the principal exchange upon which said common stock trades publicly within the 14 trading days prior to issuance. Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by The Company: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On September 28, 2015 Zander caused to be issued to the Company 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to the Company by Zander as a license initiation fee. Regen Biopharma, Inc. recognized revenue of $192,000 equivalent to the fair value of 8,000,000 of the common shares of Entest Biomedical, Inc as of the date of issuance. David R. Koos serves as sole officer and director of both Zander and Entest Biomedical, Inc. and also serves as Chairman and Chief Executive Officer of The Company.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9. COMMITMENTS AND CONTINGENCIES The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.

Stockholders Equity

Stockholders Equity	6 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders Equity	NOTE 10. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following classes of capital stock as March 31, 2016: Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 128,253,138 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 30,000 shares issued and outstanding as of March 31, 2016 and 300,000,000 is designated Series A Preferred Stock of which 84,881,697 shares are outstanding as of March 31, 2016. The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. Series AA Preferred Stock On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

Investment Securities

Investment Securities	6 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Investment Securities	11. INVESTMENT SECURITIES On September 28, 2015 Zander Theraputics, Inc. caused to be issued to Regen Biopharma, Inc. 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to Regen Biopharma, Inc. by Zander Theraputics, Inc as a license initiation fee. The common shares of Entest Biomedical, Inc described above constitute the Company’s sole investment securities as of March 31, 2016. 8,000,000 Common Shares of Entest Biomedical, Inc. Basis Fair Value Total Unrealized Losses in Other Comprehensive Income Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2016 $ 192,000 $ 56,800 (135,200 ) (63,200 )

Stock Transactions

Stock Transactions	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Stock Transactions	NOTE 10. STOCK TRANSACTIONS Common Stock On January 28, 2016 the Company issued 2,000,000 of its Common Shares for cash consideration of $100,000. On January 29, 2016 the Company issued 30,000 of its Common Shares for cash consideration of $750. On February 2, 2016 the Company issued 270,000 of its Common Shares for cash consideration of $6,750. On February 22, 2016 the Company issued 666,666 of its Common Shares for cash consideration of $33,333. On February 22, 2016 the Company issued 1,000,000 of its Common Shares for cash consideration of $12,500. Series A Preferred Stock On January 28, 2016 the Company issued 1,000,000 shares of its Series A Preferred stock for cash consideration of $50,000. On January 29, 2016 the Company issued 300,000 shares of its Series A Preferred stock for cash consideration of $7,500. On February 22, 2016 the Company issued 333,333 shares of its Series A Preferred stock for cash consideration of $16,666. On March 22, 2016 the Company issued 3,000,000 shares of its Series A Preferred stock for cash consideration of $37,500.

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	6 Months Ended
	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Restatement of Previously Issued Financial Statements	NOTE 13. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS Subsequent to the original issuance of Regen’s quarterly financial statements for the period ended March 31, 2016 the Company determined that the recognition of $ 364,822 of expenses recognized during the period resulting from the issuance for less than fair value of equity securities should not have been recognized. The following tables reflect the corrections: REGEN BIOPHARMA,INC. BALANCE SHEET As of Adjustments As of March 31, 2016 March 31, 2016 (unaudited) Restated ASSETS CURRENT ASSETS Cash 106,024 106,024 Note Receivable 12,051 12,051 Prepaid Expenses 1,000 1,000 Accrued Interest Receivable 1,978 1,978 Due from Former Employees 15,000 15,000 Total Current Assets 136,053 136,053 OTHER ASSETS Available for Sale Securities 56,800 56,800 Total Other Assets 56,800 56,800 TOTAL ASSETS 192,853 192,853 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Bank Overdraft 0 0 Accounts payable 21,283 21,283 Notes Payable 228,050 228,050 Accrued payroll taxes 1,946 1,946 Accrued Interest 31,184 31,184 Accrued Rent 15,000 15,000 Accrued Payroll 92,996 92,996 Due to Shareholder 0 0 Total Current Liabilities 390,459 390,459 Long Term Liabilities Convertible Notes Payable 58,295 58,295 Total Long Term Liabilities 58,295 58,295 Total Liabilities 448,754 448,754 STOCKHOLDERS' EQUITY (DEFICIT) Common Stock ($.0001 par value) 500,000,000 shares authorized; 114,753,938 issued and outstanding as of September 30, 2015 and 128,253,138 shares issued and outstanding March 31, 2016 12,824 12,824 Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively Series A Preferred 90,000,000 Authorized and 300,000,000 authorized, 60,981,697 and 84,881,697 outstanding as of September 30, 2105 and March 31, 2016 respectively 8,488 8,488 Series AA Preferred $0.0001 par value 600,000 authorized and 30,000 outstanding as of September 30, 2015 and March 31, 2016 3 3 Additional Paid in capital 14,551,402 (10,512,568 ) 4,038,835 Contributed Capital 728,658 728,658 Retained Earnings (Deficit) accumulated during the development stage (15,422,076 ) 10,512,568 (4,909,508 ) Accumulated Other Comprehensive Income (135,200 ) (135,200 ) Total Stockholders' Equity (Deficit) (255,901 ) (255,900 ) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) 192,853 192,853 REGEN BIOPHARMA , INC. STATEMENT OF OPERATIONS (unaudited) Quarter Ended March 31, 2016 Adjustments Quarter Ended March 31, 2016 (restated) REVENUES 0 0 COST AND EXPENSES Research and Development 172,596 172,596 General and Administrative 435,236 435,236 Consulting and Professional Fees 97,547 97,547 Rent 15,000 15,000 Total Costs and Expenses 720,379 720,379 OPERATING LOSS (720,379 ) (720,379 ) OTHER INCOME & (EXPENSES) Interest Income 297 297 Refunds of amounts previously paid Interest Expense (5,089 ) (5,089 ) Interest Expense attributable to Amortization of Discount (894 ) (894 ) Loss on issuance of common shares for less than fair value (364,822 ) 364,822 0 Preferred shares issued pursuant to contractual obligations TOTAL OTHER INCOME (EXPENSE) (370,508 ) (5,686 ) NET INCOME (LOSS) (1,090,886 ) (726,064 ) BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE (0.0087 ) (0.0058 ) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 124,875,119 124,875,119 REGEN BIOPHARMA , INC. STATEMENT OF OPERATIONS (unaudited) Six Months Ended March 31, 2016 adjustments Six Months Ended March 31, 2016 (restated) REVENUES 0 0 COST AND EXPENSES Research and Development 277,919 277,919 General and Administrative 923,831 923,831 Consulting and Professional Fees 178,080 178,080 Rent 30,000 30,000 Total Costs and Expenses 1,409,830 1,409,830 OPERATING LOSS (1,409,830 ) (1,409,830 ) OTHER INCOME & (EXPENSES) Interest Income 597 597 Refunds of amounts previously paid Interest Expense (10,090 ) (10,090 ) Interest Expense attributable to Amortization of Discount (894 ) (894 ) Loss on issuance of common shares for less than fair value (1,528,135 ) 1,528,135 0 Preferred shares issued pursuant to contractual obligations TOTAL OTHER INCOME (EXPENSE) (1,538,522 ) (10,387 ) NET INCOME (LOSS) (2,948,352 ) (1,420,217 ) BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE (0.0188 ) (0.0091 ) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 156,418,573 156,418,573 STATEMENT OF COMPREHENSIVE INCOME (unaudited) Quarter Ended March 31 2016 Adjustments 2016 (restated) Net Income (Loss) (1,090,886 ) 364,822 (726,064 ) Add: Unrealized Gains on Securities — — Less: Unrealized Losses on Securities (63,200 ) (63,200 ) Total Other Comprehensive Income (Loss) (63,200 ) (63,200 ) Comprehensive Income (1,154,086 ) (789,264 ) Six Months Ended March 31 2016 Adjustments 2016 (restated) Net Income (Loss) (2,948,352 ) 1,528,135 (1,420,217 ) Add: Unrealized Gains on Securities — — Less: Unrealized Losses on Securities (101,600 ) (101,600 ) Total Other Comprehensive Income (Loss) (101,600 ) (101,600 ) Comprehensive Income (3,049,952 ) (1,521,817 ) REGEN BIOPHARMA , INC. STATEMENT OF CASH FLOWS (unaudited) Six Months Ended adjustments Six Months Ended March 31 2016 March 31 2016 CASH FLOWS FROM OPERATING ACTIVITIES Net Income (loss) (2,948,352 ) $ 1,528,135 (1,420,217 ) Adjustments to reconcile net Income to net cash Preferred Stock Issued for Expenses Preferred Stock issued for Interest Preferred Stock issued pursuant to contractual obligations Common Stock issued to Consultants Preferred Stock issued to Consultants 40 40 Increase (Decrease) in Interest expense attributable to amortization of Discount 894 894 Changes in operating assets and liabilities: Increase (Decrease) in Accounts Payable (4,571 ) (4,571 ) (Increase) Decrease in Notes Receivable (Increase) Decrease in Interest Receivable (597 ) (597 ) Increase ( Decrease) in Bank Overdraft Increase (Decrease) in accrued Expenses 72,093 72,093 (Increase) Decrease in Prepaid Expenses 9,000 9,000 (Increase)Decrease in Due from Former Employee (15,000 ) (15,000 ) Increase in issuance of stock below fair value 1,528,135 $ (1,528,135 ) 0 Increase in Additional Paid in Capital 495,462 495,462 Net Cash Provided by (Used in) Operating (862,896 ) (862,896 ) CASH FLOWS FROM FINANCING ACTIVITIES Common Stock issued for Cash 475,000 475,000 Preferred Stock issued for Cash 350,001 350,001 Increase in Contributed Capital Increase ( Decrease) in Notes Payable 5,299 5,299 Increase in Convertible Notes payable 100,000 100,000 Increase in Due to Shareholder 0 0 Net Cash Provided by (Used in) Financing 930,300 930,300 Net Increase (Decrease) in Cash 67,404 67,404 Cash at Beginning of Period 38,620 38,620 Cash at End of Period 106,024 106,024 Supplemental Disclosure of Noncash investing and financing activities: Common shares Issued for Debt Preferred Shares Issued for Debt

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	NOTE 12: SUBSEQUENT EVENTS On April 7, 2016 Regen Biopharma, Inc. (“Regen”) issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to David Koos, Regen’s Chief Executive Officer, as consideration for efforts expended by Koos with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate.. On April 7, 2016 Regen Biopharma, Inc. (“Regen”) issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to Harry Lander , Regen’s President and Chief Scientific Officer, as consideration for efforts expended by Lander with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate. On April 7, 2016 Regen Biopharma, Inc. (“Regen”) issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to Tod Caven , Regen’s Chief Financial Officer, as consideration for efforts expended by Caven with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate. On April 7, 2016 Regen Biopharma, Inc. (“Regen”) issued 1,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) in settlement of $10,000 of principal indebtedness.

Organization and Summary of S21

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
USE OF ESTIMATES	B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS	C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
PROPERTY AND EQUIPMENT	D. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
FAIR VALUE OF FINANCIAL INSTRUMENTS	E. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
INCOME TAXES	F. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31, 2016 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	G. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
ADVERTISING	H. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended March 31, 2016 and $0 for the three months ended March 31, 2015.

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Notes Payable	March 31, 2016 David Koos ( Note 8) 50 Bio Technology Partners Business Trust 36,000 Bostonia Partners 189,000 Blackbriar Partners (Note 8) 3,000 Notes payable $ 228,050

Notes Receivable (Tables)

Notes Receivable (Tables)	6 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Notes Receivable	March 31, 2016 Entest Biomedical, Inc. (Note 8) $ 12,051 Notes Receivable $ 12,051

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Deferred tax assets	Deferred tax assets: Net operating tax carry forwards $ 5,243,336 Other -0- Gross deferred tax assets 5,243,336 Valuation allowance (5,243,336 Net deferred tax assets $ -0-

Investment Securities (Tables)

Investment Securities (Tables)	6 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Comprehensive Income	8,000,000 Common Shares of Entest Biomedical, Inc. Basis Fair Value Total Unrealized Losses in Other Comprehensive Income Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2016 $ 192,000 $ 56,800 (135,200 ) (63,200 )

Restatement of Previously Iss26

Restatement of Previously Issued Financial Statements (Tables) - Restatement	6 Months Ended
	Mar. 31, 2016
Restatement of Consolidated Balance Sheeet	REGEN BIOPHARMA,INC. BALANCE SHEET As of Adjustments As of March 31, 2016 March 31, 2016 (unaudited) Restated ASSETS CURRENT ASSETS Cash 106,024 106,024 Note Receivable 12,051 12,051 Prepaid Expenses 1,000 1,000 Accrued Interest Receivable 1,978 1,978 Due from Former Employees 15,000 15,000 Total Current Assets 136,053 136,053 OTHER ASSETS Available for Sale Securities 56,800 56,800 Total Other Assets 56,800 56,800 TOTAL ASSETS 192,853 192,853 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Bank Overdraft 0 0 Accounts payable 21,283 21,283 Notes Payable 228,050 228,050 Accrued payroll taxes 1,946 1,946 Accrued Interest 31,184 31,184 Accrued Rent 15,000 15,000 Accrued Payroll 92,996 92,996 Due to Shareholder 0 0 Total Current Liabilities 390,459 390,459 Long Term Liabilities Convertible Notes Payable 58,295 58,295 Total Long Term Liabilities 58,295 58,295 Total Liabilities 448,754 448,754 STOCKHOLDERS' EQUITY (DEFICIT) Common Stock ($.0001 par value) 500,000,000 shares authorized; 114,753,938 issued and outstanding as of September 30, 2015 and 128,253,138 shares issued and outstanding March 31, 2016 12,824 12,824 Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively Series A Preferred 90,000,000 Authorized and 300,000,000 authorized, 60,981,697 and 84,881,697 outstanding as of September 30, 2105 and March 31, 2016 respectively 8,488 8,488 Series AA Preferred $0.0001 par value 600,000 authorized and 30,000 outstanding as of September 30, 2015 and March 31, 2016 3 3 Additional Paid in capital 14,551,402 (10,512,568 ) 4,038,835 Contributed Capital 728,658 728,658 Retained Earnings (Deficit) accumulated during the development stage (15,422,076 ) 10,512,568 (4,909,508 ) Accumulated Other Comprehensive Income (135,200 ) (135,200 ) Total Stockholders' Equity (Deficit) (255,901 ) (255,900 ) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) 192,853 192,853
Restatement of Statement of Operations	REGEN BIOPHARMA , INC. STATEMENT OF OPERATIONS (unaudited) Quarter Ended March 31, 2016 Adjustments Quarter Ended March 31, 2016 (restated) REVENUES 0 0 COST AND EXPENSES Research and Development 172,596 172,596 General and Administrative 435,236 435,236 Consulting and Professional Fees 97,547 97,547 Rent 15,000 15,000 Total Costs and Expenses 720,379 720,379 OPERATING LOSS (720,379 ) (720,379 ) OTHER INCOME & (EXPENSES) Interest Income 297 297 Refunds of amounts previously paid Interest Expense (5,089 ) (5,089 ) Interest Expense attributable to Amortization of Discount (894 ) (894 ) Loss on issuance of common shares for less than fair value (364,822 ) 364,822 0 Preferred shares issued pursuant to contractual obligations TOTAL OTHER INCOME (EXPENSE) (370,508 ) (5,686 ) NET INCOME (LOSS) (1,090,886 ) (726,064 ) BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE (0.0087 ) (0.0058 ) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 124,875,119 124,875,119 REGEN BIOPHARMA , INC. STATEMENT OF OPERATIONS (unaudited) Six Months Ended March 31, 2016 adjustments Six Months Ended March 31, 2016 (restated) REVENUES 0 0 COST AND EXPENSES Research and Development 277,919 277,919 General and Administrative 923,831 923,831 Consulting and Professional Fees 178,080 178,080 Rent 30,000 30,000 Total Costs and Expenses 1,409,830 1,409,830 OPERATING LOSS (1,409,830 ) (1,409,830 ) OTHER INCOME & (EXPENSES) Interest Income 597 597 Refunds of amounts previously paid Interest Expense (10,090 ) (10,090 ) Interest Expense attributable to Amortization of Discount (894 ) (894 ) Loss on issuance of common shares for less than fair value (1,528,135 ) 1,528,135 0 Preferred shares issued pursuant to contractual obligations TOTAL OTHER INCOME (EXPENSE) (1,538,522 ) (10,387 ) NET INCOME (LOSS) (2,948,352 ) (1,420,217 ) BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE (0.0188 ) (0.0091 ) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 156,418,573 156,418,573
Restatement of Statement of Comprehensive Income	STATEMENT OF COMPREHENSIVE INCOME (unaudited) Quarter Ended March 31 2016 Adjustments 2016 (restated) Net Income (Loss) (1,090,886 ) 364,822 (726,064 ) Add: Unrealized Gains on Securities — — Less: Unrealized Losses on Securities (63,200 ) (63,200 ) Total Other Comprehensive Income (Loss) (63,200 ) (63,200 ) Comprehensive Income (1,154,086 ) (789,264 ) Six Months Ended March 31 2016 Adjustments 2016 (restated) Net Income (Loss) (2,948,352 ) 1,528,135 (1,420,217 ) Add: Unrealized Gains on Securities — — Less: Unrealized Losses on Securities (101,600 ) (101,600 ) Total Other Comprehensive Income (Loss) (101,600 ) (101,600 ) Comprehensive Income (3,049,952 ) (1,521,817 )
Restatement of Statment of Cashflows	REGEN BIOPHARMA , INC. STATEMENT OF CASH FLOWS (unaudited) Six Months Ended adjustments Six Months Ended March 31 2016 March 31 2016 CASH FLOWS FROM OPERATING ACTIVITIES Net Income (loss) (2,948,352 ) $ 1,528,135 (1,420,217 ) Adjustments to reconcile net Income to net cash Preferred Stock Issued for Expenses Preferred Stock issued for Interest Preferred Stock issued pursuant to contractual obligations Common Stock issued to Consultants Preferred Stock issued to Consultants 40 40 Increase (Decrease) in Interest expense attributable to amortization of Discount 894 894 Changes in operating assets and liabilities: Increase (Decrease) in Accounts Payable (4,571 ) (4,571 ) (Increase) Decrease in Notes Receivable (Increase) Decrease in Interest Receivable (597 ) (597 ) Increase ( Decrease) in Bank Overdraft Increase (Decrease) in accrued Expenses 72,093 72,093 (Increase) Decrease in Prepaid Expenses 9,000 9,000 (Increase)Decrease in Due from Former Employee (15,000 ) (15,000 ) Increase in issuance of stock below fair value 1,528,135 $ (1,528,135 ) 0 Increase in Additional Paid in Capital 495,462 495,462 Net Cash Provided by (Used in) Operating (862,896 ) (862,896 ) CASH FLOWS FROM FINANCING ACTIVITIES Common Stock issued for Cash 475,000 475,000 Preferred Stock issued for Cash 350,001 350,001 Increase in Contributed Capital Increase ( Decrease) in Notes Payable 5,299 5,299 Increase in Convertible Notes payable 100,000 100,000 Increase in Due to Shareholder 0 0 Net Cash Provided by (Used in) Financing 930,300 930,300 Net Increase (Decrease) in Cash 67,404 67,404 Cash at Beginning of Period 38,620 38,620 Cash at End of Period 106,024 106,024 Supplemental Disclosure of Noncash investing and financing activities: Common shares Issued for Debt Preferred Shares Issued for Debt The Accompanying Notes are an Integral Part of These Financial Statements

Organization and Summary of S27

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016
Accounting Policies [Abstract]
Advertising expenses	$ 0	$ 0
Valuation allowance			100.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended	47 Months Ended
	Mar. 31, 2016	Mar. 31, 2016	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss)			$ (15,421,576)
Issuance of equity securities for cash	$ 265,000	$ 825,001
Issuance of convertible debt	$ 100,000	$ 100,000

Notes Payable and Convertible N

Notes Payable and Convertible Notes Payable - Notes Payable (Details)	Mar. 31, 2016USD ($)
Notes Payable	$ 228,050
David Koos
Notes Payable	50
Bio Technology Partners Business Trust
Notes Payable	36,000
Bostonia Partners
Notes Payable	189,000
Blackbriar Partners
Notes Payable	$ 3,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative)	6 Months Ended
	Mar. 31, 2016USD ($)
David Koos
Note payable	$ 50
Interest rate per annum	15.00%
Bio Technology Partners Business Trust
Note payable	$ 36,000
Interest rate per annum	10.00%
Bostonia Partners
Note payable	$ 60,000
Interest rate per annum	10.00%
Maturity Date	Sep. 16, 2016
Bostonia Partners #2
Note payable	$ 59,000
Interest rate per annum	10.00%
Maturity Date	Sep. 22, 2016
Bostonia Partners #3
Note payable	$ 20,000
Interest rate per annum	10.00%
Maturity Date	Feb. 19, 2017
Bostonia Partners #4
Note payable	$ 30,000
Interest rate per annum	10.00%
Maturity Date	Feb. 24, 2017
Bostonia Partners #5
Note payable	$ 20,000
Interest rate per annum	10.00%
Maturity Date	Mar. 8, 2017
Blackbriar Partners
Note payable	$ 3,000
Interest rate per annum	10.00%
Maturity Date	Feb. 19, 2017

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 08, 2016
Debt Disclosure [Abstract]
Convertible note issued	$ 100,000	$ 100,000
Convertible note, interest rate		8.00%
Convertible note, terms	(a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property
Beneficial conversion feature	$ 42,600
Unamortized discount	$ 41,705

Notes Receivable - Notes Receiv

Notes Receivable - Notes Receivable (Details)	Mar. 31, 2016USD ($)
Notes Receivable	$ 12,051
Entest Biomedical, Inc
Notes Receivable	$ 12,051

Notes Receivable (Details Narra

Notes Receivable (Details Narrative)	6 Months Ended
	Mar. 31, 2016USD ($)
Notes Receivable	$ 12,051
Entest Biomedical, Inc
Notes Receivable	$ 12,051
Interest rate per annum	10.00%

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets (Details)	Mar. 31, 2016USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 5,243,336
Other	0
Gross deferred tax assets	5,243,336
Valuation allowance	(5,243,336)
Net deferred tax assets	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	6 Months Ended
	Mar. 31, 2016USD ($)
Income Tax Disclosure [Abstract]
Deferred Tax Asset	$ 5,243,336
Net operating loss carry forwards	$ 15,421,576
Federal corporate rate	34.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended	38 Months Ended
	Dec. 31, 2015	Mar. 31, 2016	Jun. 30, 2015	Sep. 30, 2015
Capital contributions from related party			$ 728,658
Common shares issued to BMSN			50,010,000
Value of shares issued to BMSN			$ 20,090
Monthly rent payable to Entest		$ 5,000
Notes Receivable		12,051
Notes Payable		228,050
Payments to notes payable	$ 19,701
License fee		$ 100,000
Royalties receivable, percentage		4.00%
Royalties, receivable		$ 10,000
Common shares issued in satisfaction of license fee		8,000,000
Bio Matrix Scientific Group, Inc
Notes Payable				$ 19,701
David Koos
Interest rate per annum		15.00%
Notes Payable		$ 50
Blackbriar Partners
Interest rate per annum		10.00%
Notes Payable		$ 3,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	6 Months Ended
	Mar. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
Monthly rent payable to Entest	$ 5,000

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - $ / shares	6 Months Ended
	Mar. 31, 2016	Apr. 07, 2016	Mar. 22, 2016	Feb. 22, 2016	Feb. 02, 2016	Jan. 29, 2016	Jan. 28, 2016	Sep. 30, 2015
Common stock, Par value	$ 0.0001							$ 0.0001
Common stock, authorized	500,000,000							500,000,000
Common stock issued and outstanding	128,253,138				270,000	30,000	2,000,000	114,753,938
Preferred stock, par value	$ 0.0001							$ .0001
Preferred stock, authorized	800,000,000							100,000,000
Series A Preferred Stock
Preferred stock, par value	$ .0001							$ 0.0001
Preferred stock, authorized	300,000,000							90,000,000
Preferred stock, shares issued and outstanding	84,881,697	1,000,000	3,000,000	333,333		300,000	1,000,000	60,981,697
Preferred stock, shares outstanding	84,881,697							60,981,697
Preferred stock, non-cumulative cash dividends	$ .01
Preferred shares voting	On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders.
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001							$ 0.0001
Preferred stock, authorized	600,000							600,000
Preferred stock, shares issued and outstanding	30,000							30,000
Preferred stock, shares outstanding	30,000							30,000
Preferred shares voting	On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Investment Securities (Details)

Investment Securities (Details)	3 Months Ended
	Mar. 31, 2016USD ($)
Accounting Policies [Abstract]
Investment Securities, Basis	$ 192,000
Investment Securities, Total Unrealized Losses	135,200
Investment Securities, Net Unrealized Loss during the quarter	$ 63,200

Investment Securities (Details

Investment Securities (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 28, 2015
Accounting Policies [Abstract]
Stock issued as license fee, shares		8,000,000
Stock issued as license fee, value		$ 100,000
Common shares of Entest Biomedical, Inc	8,000,000

Stock Transactions (Details Nar

Stock Transactions (Details Narrative) - USD ($)	Apr. 07, 2016	Mar. 31, 2016	Mar. 22, 2016	Feb. 22, 2016	Feb. 02, 2016	Jan. 29, 2016	Jan. 28, 2016	Sep. 30, 2015
Common Shares issued		128,253,138			270,000	30,000	2,000,000	114,753,938
Cash consideration					$ 6,750	$ 750	$ 100,000
Series A Preferred Stock
Preferred stock, shares issued	1,000,000	84,881,697	3,000,000	333,333		300,000	1,000,000	60,981,697
Preferred stock value			$ 37,500	$ 16,666		$ 7,500	$ 50,000
Transaction #1
Common Shares issued				666,666
Cash consideration				$ 33,333
Transaction #2
Common Shares issued				1,000,000
Cash consideration				$ 12,500

Restatement of Balance Sheets (

Restatement of Balance Sheets (Details) - USD ($)	Apr. 07, 2016	Mar. 31, 2016	Feb. 02, 2016	Jan. 29, 2016	Jan. 28, 2016	Sep. 30, 2015
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 114,753,938 issued and outstanding as of September 30, 2015 and 124,287,272 shares issued and outstanding December 31, 2015			$ 6,750	$ 750	$ 100,000
Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively	$ 10,000
Original
CURRENT ASSETS
Cash		$ 106,024
Note Receivable		12,051
Prepaid Expenses		1,000
Accrued Interest Receivable		1,978
Due from Former Employees		15,000
Total Current Assets		136,053
OTHER ASSETS
Available for Sale Securities		56,800
Total Other Assets		56,800
TOTAL ASSETS		192,853
Current Liabilities:
Bank Overdraft		0
Accounts payable		21,283
Notes Payable		228,050
Accrued payroll taxes		1,946
Accrued Interest		31,184
Accrued Rent		15,000
Accrued Payroll		92,996
Due to Shareholder		0
Total Current Liabilities		390,459
Total Liabilities		448,754
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 114,753,938 issued and outstanding as of September 30, 2015 and 124,287,272 shares issued and outstanding December 31, 2015		12,824
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively
Additional Paid in capital		14,551,402
Contributed Capital		728,658
Retained Earnings (Deficit) accumulated during the development stage		(15,422,076)
Accumulated other comprehensive income		(135,200)
Total Stockholders' Equity (Deficit)		(255,900)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		192,853
Original | Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively		8,025
Original | Series AA
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively		3
Adjustments
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively
Additional Paid in capital		(10,512,568)
Retained Earnings (Deficit) accumulated during the development stage		10,515,568
Adjustments | Series A
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively
Adjustments | Series AA
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively
Restatement
CURRENT ASSETS
Cash		106,024				$ 38,620
Note Receivable		12,051				12,051
Prepaid Expenses		1,000				10,000
Accrued Interest Receivable		1,978				1,381
Due from Former Employees		15,000
Total Current Assets		136,053				62,052
OTHER ASSETS
Available for Sale Securities		56,800				158,400
Total Other Assets		56,800				158,400
TOTAL ASSETS		192,853				220,452
Current Liabilities:
Bank Overdraft		0				0
Accounts payable		21,283				25,854
Notes Payable		228,050				222,751
Accrued payroll taxes		1,946				1,940
Accrued Interest		31,184				21,093
Accrued Rent		15,000				10,000
Accrued Payroll		92,996				36,001
Due to Shareholder		0
Total Current Liabilities		390,459				317,639
Total Liabilities		448,754				317,639
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 114,753,938 issued and outstanding as of September 30, 2015 and 124,287,272 shares issued and outstanding December 31, 2015		12,824				11,474
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively
Additional Paid in capital		4,038,835				2,679,473
Contributed Capital		728,658				728,658
Retained Earnings (Deficit) accumulated during the development stage		(4,909,508)				(3,489,293)
Accumulated other comprehensive income		(135,200)				(33,600)
Total Stockholders' Equity (Deficit)		(255,900)				(97,187)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		192,853				220,452
Restatement | Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively		8,488				$ 6,098
Restatement | Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock, 0.0001 par value, 800,000,000 authorized and 100,000,000 authorized as of December 31, 2015 and September 30, 2015 respectively		$ 3

Restatment of Statements of Ope

Restatment of Statements of Operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Original
REVENUES	$ 0		$ 0
COST AND EXPENSES
Research and Development	172,596		277,919
General and Administrative	435,236		923,831
Consulting and Professional Fees	97,547		178,080
Rent	15,000		30,000
Total Costs and Expenses	720,379		1,409,830
OPERATING LOSS	(720,379)		(1,409,830)
OTHER INCOME & (EXPENSES)
Interest Income	297		597
Refunds of amounts previously paid
Interest Expense	(5,089)		(10,090)
Interest Expense attributable to Amortization Discount	(894)		(894)
Loss on issuance of common shares for less than fair value	(364,822)		(1,528,135)
Preferred shares issued pursuant to contractual obligations
TOTAL OTHER INCOME (EXPENSE)	(370,508)		(1,538,522)
Net Income (Loss)	$ (1,090,886)		$ (2,948,352)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.0087)		$ (0.0188)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	124,875,119		156,418,573
Adjustments
OTHER INCOME & (EXPENSES)
Loss on issuance of common shares for less than fair value	$ 364,822		$ 1,528,135
Net Income (Loss)	364,822		1,528,135
Restatement
REVENUES	0	$ 0	0	$ 0
COST AND EXPENSES
Research and Development	172,596	22,969	277,919	25,206
General and Administrative	435,236	303,536	923,831	442,989
Consulting and Professional Fees	97,547	279,913	178,080	339,761
Rent	15,000	15,000	30,000	26,871
Total Costs and Expenses	720,379	621,419	1,409,830	834,828
OPERATING LOSS	(720,379)	(621,419)	(1,409,830)	(834,828)
OTHER INCOME & (EXPENSES)
Interest Income	297	291	597	551
Refunds of amounts previously paid
Interest Expense	(5,089)	(9,188)	(10,090)	(15,230)
Interest Expense attributable to Amortization Discount	(894)		(894)
Loss on issuance of common shares for less than fair value	0		0
Preferred shares issued pursuant to contractual obligations		(3,154)		(3,154)
TOTAL OTHER INCOME (EXPENSE)	(5,686)	(12,051)	(10,387)	(17,833)
Net Income (Loss)	$ (726,064)	$ (633,470)	$ (1,420,217)	$ (852,661)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.0058)	$ (0.0088)	$ (0.0091)	$ (0.0092)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	124,875,119	71,986,230	156,418,573	93,139,424

Restatment of Staments of Compr

Restatment of Staments of Comprehensive Income (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Original
Net Income (Loss)	$ (1,090,886)		$ (2,948,352)
Add:
Unrealized Gains on Securities	0		0
Less:
Unrealized Losses on Securities	(63,200)		(101,600)
Total Other Comprehensive Income (Loss)	(63,200)		(101,600)
Comprehensive Income	(1,154,086)		(3,049,952)
Adjustments
Net Income (Loss)	364,822		1,528,135
Restatement
Net Income (Loss)	(726,064)	$ (633,470)	(1,420,217)	$ (852,661)
Add:
Unrealized Gains on Securities	0	0	0	0
Less:
Unrealized Losses on Securities	(63,200)	0	(101,600)	0
Total Other Comprehensive Income (Loss)	(63,200)	0	(101,600)	0
Comprehensive Income	$ (789,264)	$ (633,470)	$ (1,521,817)	$ 852,661

Restatement of Cashflows (Detai

Restatement of Cashflows (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Original
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (1,090,886)		$ (2,948,352)
Adjustments to reconcile net Income to net cash
Preferred Stock issued for Expenses
Preferres Stock issued for Interest
Preferred Stock issued pursuant to contractual obligations
Common Stock issued to Consultants
Preferred Stock issued to Consultants			40
Increase (Decrease) in Interest expense attributable to amortization of Discount	894		894
Increase (Decrease) in Accounts Payable			(4,571)
(Increase) Decrease in Notes Receivable
(Increase) Decrease in Interest Receivable			(597)
Increase (Decrease) in Bank Overdraft
Increase (Decrease) in Accrued Expenses			72,093
(Increase) Decrease in Prepaid Expenses			9,000
(Increase) Decrease in Due from Former Employee			(15,000)
Increase in issuance of stock below fair value	364,822		1,528,135
Increase in Additional Paid in Capital			495,462
Net Cash Provided by (Used in) Operating Activities			(862,896)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash			475,000
Preferred Stock issued for Cash			350,001
Increase in Contributed Capital
Increase (Decrease) in Notes Payable			5,299
Increase in Convertible Notes Payable			100,000
Increase in Due to Shareholder			0
Net Cash Provided by (Used in) Financing Activities			930,300
Net Increase (Decrease) in Cash			67,404
Cash at Beginning of Period			38,620
Cash at End of Period	106,024		106,024
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt
Preferred Shares Issued for Debt
Adjustments
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	364,822		1,528,135
Adjustments to reconcile net Income to net cash
Increase in issuance of stock below fair value	(364,822)		(1,528,135)
Restatement
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	(726,064)	$ (633,470)	(1,420,217)	$ (852,661)
Adjustments to reconcile net Income to net cash
Preferred Stock issued for Expenses				100
Preferres Stock issued for Interest				891
Preferred Stock issued pursuant to contractual obligations				3,154
Common Stock issued to Consultants				226,177
Preferred Stock issued to Consultants			40	420
Increase (Decrease) in Interest expense attributable to amortization of Discount	894		894
Increase (Decrease) in Accounts Payable			(4,571)	12,902
(Increase) Decrease in Notes Receivable				(1,629)
(Increase) Decrease in Interest Receivable			(597)	(551)
Increase (Decrease) in Bank Overdraft				(6,137)
Increase (Decrease) in Accrued Expenses			72,093	19,437
(Increase) Decrease in Prepaid Expenses			9,000
(Increase) Decrease in Due from Former Employee			(15,000)
Increase in issuance of stock below fair value	0		0
Increase in Additional Paid in Capital			495,462	132,603
Net Cash Provided by (Used in) Operating Activities			(862,896)	(465,294)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash			475,000
Preferred Stock issued for Cash			350,001
Increase in Contributed Capital				85,000
Increase (Decrease) in Notes Payable			5,299	19,582
Increase in Convertible Notes Payable			100,000	882,685
Increase in Due to Shareholder			0
Net Cash Provided by (Used in) Financing Activities			930,300	987,267
Net Increase (Decrease) in Cash			67,404	521,974
Cash at Beginning of Period			38,620	0
Cash at End of Period	$ 106,024	$ 521,974	106,024	521,974
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt				882,868
Preferred Shares Issued for Debt				$ 6,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Apr. 07, 2016	Mar. 31, 2016	Mar. 22, 2016	Feb. 22, 2016	Jan. 29, 2016	Jan. 28, 2016	Sep. 30, 2015
Series A Preferred Stock | Harry Lander
Preferred stock, shares issued	10,000,000
Series A Preferred Stock
Preferred stock, shares issued	1,000,000	84,881,697	3,000,000	333,333	300,000	1,000,000	60,981,697
Preferred Stock issued in settlement of Debt	$ 10,000
Series A Preferred Stock | Todd Caven
Preferred stock, shares issued	10,000,000
Series A Preferred Stock | David Koos
Preferred stock, shares issued	10,000,000